Anika Therapeutics Inc.
32 Wiggins Avenue
Bedford,
MA 01730
United States - Map
Phone: 781-457-9000
Fax: 781-305-9720
Web Site: http://www.anikatherapeutics.com
| Anika Therapeutics, Inc. develops, manufactures, and commercializes therapeutic products for tissue protection, healing, and repair. Its products are based on hyaluronic acid (HA), a naturally occurring biocompatible polymer found in the body. The company offers ORTHOVISC, an HA product used in the treatment of some forms of osteoarthritis in humans; and AMVISC, AMVISC Plus, STAARVISC-II, and ShellGel that are injectable ophthalmic viscoelastic HA products used as viscoelastic agents in ophthalmic surgical procedures, such as cataract extraction and intraocular lens implantation. It also provides HYVISC, an HA product used in the treatment of equine osteoarthritis; INCERT, an HA based anti-adhesive for surgical applications; and ORTHOVISC mini, a treatment for osteoarthritis targeting small joints. In addition, the company offers MONOVISC, a single-injection osteoarthritis product for the treatment of joint dysfunction in horses due to non-infectious synovitis associated with equine osteoarthritis; and ELEVESS, which is designed as a family of aesthetic dermatology products for facial wrinkles, scar remediation, and lip augmentation. Further, it involves in the research and development of joint health related products, such as a single-injection treatment product that uses a non-animal source HA. Anika Therapeutics, Inc. offers its products in the United States, as well as in Canada, Europe, Turkey, the Middle East, and Asia through representatives, agents, and distributors. The company was founded in 1983 and is headquartered in Bedford, Massachusetts. |
|
| Key Statistics |
| |
| | Pay | Exercised | Dr. Charles H. Sherwood Ph.D., 62
Chief Exec. Officer, Pres |
$
621.00K |
$
239.00K | Mr. Kevin W. Quinlan , 59
Chief Financial Officer, Principal Accounting Officer, Treasurer and Sec. |
$
324.00K |
$
0 | Dr. Andrew J. Carter Ph.D, 53
Chief Technology Officer |
$
292.00K |
$
0 | Mr. William J. Mrachek , 65
VP of HR |
$
261.00K |
$
0 | Mrs. Irina B. Kulinets , 54
VP of Regulatory & Clinical Affairs |
$
299.00K |
$
0 |
|
|
|
Dollar amounts are as of
31-Dec-08
and compensation values are for the last fiscal
year ending on that date. "Pay" is salary, bonuses, etc. "Exercised" is the value of
options exercised during the fiscal year.
| |
|
1.23% Nasdaq 
Profile
